Santhera Pharmaceuticals company information, Employees & Contact Information

Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Yahoo Finance

BRIEF—Santhera inks deal for Agamree distribution in Russia The Pharma Letter

Santhera extends Highbridge convertible bond to 30th September 2025 Yahoo Finance

Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia The Manila Times

Santhera, Ikris Sign Agreement for Distribution of AGAMREE in India Contract Pharma

Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC PMLiVE

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries Yahoo Finance

Santhera secures 20 million francs growth funding for Agamree rollout The Pharma Letter

Baker McKenzie Advises Highbridge Capital Management, LLC on its Additional CHF 10 Million Investment in Santhera Pharmaceuticals via Convertible Bond Baker McKenzie

Santhera, Ikris Pharma sign distribution agreement for DMD drug Pharmaceutical Technology

Agamree for Duchenne muscular dystrophy available by prescription in US Healio

Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India Yahoo Finance

Santhera's drug gets US FDA nod for rare muscular dystrophy Reuters

Santhera continues global rollout of Agamree with Indian deal The Pharma Letter

Santhera Pharmaceuticals Reports Strong H1 2025 Growth TipRanks

Destiny calls time on SporeGen COVID collab, while Santhera hands lonodelestat back to Spexis Fierce Biotech

Santhera and Catalyst to market DMD drug vamorolone in North America Pharmaceutical Technology

Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout Yahoo Finance

Santhera partners with Clinigen to expand Agamree access The Pharma Letter

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals Yahoo Finance

Santhera, making good on its debts, offloads North American rights for DMD drug to Catalyst for up to $231M Fierce Biotech

Final NICE nod for Santhera’s Agamree The Pharma Letter

Santhera preps UK Duchenne drug launch after NICE says yes pharmaphorum

Santhera fully divests rare eye disease drug Raxone to Chiesi Pharmaceutical Technology

After FDA efforts finally get rolling, Santhera DMD drug sidelined by manufacturing delay Fierce Biotech

Santhera’s Earnings Call: Positive Outlook Amid Challenges TipRanks

Drug development progress in duchenne muscular dystrophy Frontiers

NICE backs Santhera’s Agamree for DMD The Pharma Letter

GENESIS to distribute Santhera’s Agamree in Central and Eastern Europe The Pharma Letter

Santhera, Catalyst score FDA nod for Duchenne drug. Can they gain more indications for Agamree? Fierce Pharma

Santhera licences vamorolone rights to Catalyst Pharmaceuticals European Biotechnology Magazine

Santhera sends pulmonary drug to back of queue as DMD asset swallows funding Fierce Biotech

Investors Don't See Light At End Of Santhera Pharmaceuticals Holding AG's (VTX:SANN) Tunnel And Push Stock Down 26% simplywall.st

Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application Fierce Biotech

Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen Fierce Biotech

Santhera outlines cuts, and they are deep, as CMO hits the exit Fierce Biotech

MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree PMLiVE

Drug to Possibly Treat DMD, Idebenone (Raxone), Under CHMP Review in Europe Muscular Dystrophy News

Santhera partners with Ikris Pharma Network for distribution of AGAMREE® in India BioSpectrum India

Santhera CEO Klaus Schollmeier joins SuppreMol PMLiVE